Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
354.5 USD | -0.01% | +0.59% | +18.37% |
Apr. 26 | Well, it isn't as bad as feared... | |
Apr. 26 | The Cigna Group Enters Revolving Credit Facility | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.52 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.37% | 101B | B- | ||
-5.91% | 456B | B- | ||
+13.93% | 125B | A- | ||
-0.28% | 39.69B | B- | ||
-33.18% | 36.86B | A- | ||
-5.28% | 20.05B | B- | ||
-13.82% | 3.08B | C+ | ||
-28.58% | 337M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CI Stock
- Ratings Cigna